Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

Inclusion Criteria: * Written informed consent to participate in this trial prior to any study-mandated procedure. * Male subjects aged 18 to 35 years inclusive. * Subjects have to agree to use a reliable way of contraception with their partners from study entry until one month after study drug administration. * BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg and an upper limit of 100 kg. * Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters. Exclusion Criteria: * Unwillingness to abstain from any medication, including recreational drugs or vitamin supplements during the course of the study and within two days prior to the treatment day. * Unwillingness to abstain from alcohol within one day prior to the treatment day until one day after the treatment day. * Surgery or trauma with significant blood loss or blood donation within one month prior to the treatment day. * History, signs or symptoms of cardiovascular disease, in particular: * History of frequent vasovagal collapse or of orthostatic hypotension * Resting pulse rate ≤45 or ≥100 beats/min * Hypertension (RR systolic \>160 or RR diastolic \>90 mmHg) * Hypotension (RR systolic \<100 or RR diastolic \<50 mmHg) * Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complex bundle branch block * Any chronic cardiac arrhythmias (except PAC's, PVC's) * Renal impairment: plasma creatinine \>120 μmol/L * Liver function tests (alkaline phosphatase, AST, ALT and/or γ-GT) above 2x the upper limit of normal. * History of asthma * Atopic constitution * CRP above 2x the upper limit of normal, or clinically significant acute illness, including infections, within two weeks prior to the treatment day. * Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to the treatment day. * Known or suspected of not being able to comply with the trial protocol. * Known hypersensitivity or allergic reactions to drug compounds, (i.e. previous adverse drug reactions). * Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.